SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Franklin D. Roosevelt — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFranklin D. Roosevelt
Date of birth1882-01-30
IdentifiersMRN HR-ET002-SYN-TD; SSN (made up) 000-02-5130
Document date1944-06-26
AuthorNathaniel Brooks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month heart failure and blood pressure review. [S]

History of Present Illness

Mr. Roosevelt returns for his three-month review. He propels his wheelchair on level ground without stopping and is breathless only on long ramps. He sleeps on one pillow and has had no leg swelling for several weeks. His home weights have held at 83 to 84 kg for a month, and his home blood pressures run in the 120s over 70s. He felt more energetic within a few weeks of the iron infusions and is working full days again. He has had no lightheadedness on transfers, no breast tenderness on spironolactone, and no muscle aches on atorvastatin. He has not smoked since April, cravings are now rare, and he asks to stop the patch. [S]

ElementDetail
Interval changeLevel ground without stopping; breathless only on long ramps; one pillow; no edema
Weight logStable at 83 to 84 kg for a month
Home blood pressure120s over 70s
Medication toleranceNo lightheadedness, breast tenderness, or muscle aches
FunctionWorking full days again
TobaccoNo cigarettes since April; rare cravings
NYHA classII

Review of Systems

SystemResultFinding
ConstitutionalNegativeMore energy since the iron infusions; no fever
CardiovascularNegativeNo chest pain, palpitations, orthopnea, or leg swelling
RespiratoryPositiveBreathless only on long ramps; morning cough fading
GenitourinaryNegativeNo dysuria or genital itching
NeurologicalNegativeNo lightheadedness on transfers
MusculoskeletalNegativeNo muscle aches or cramps
PsychiatricNegativeMood good; PHQ-2 score 0

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route1944-03-27 to 1944-04-10completedS
Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route1944-04-10activeS
Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route1944-03-27 to 1944-04-10completedS
Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route1944-04-10 to 1944-06-26completedS
Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route1944-06-26activeS
Spironolactone 25 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1944-04-10activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1944-03-27activeS
Furosemide 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1944-03-27 to 1944-06-26completedS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1944-03-27activeS
Nicotine 21 mg/24 hr transdermal patch, apply one patch dailyApply one patch to the skin dailyTopical route1944-03-27 to 1944-06-26completedS
Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart750 mg intravenously, two doses one week apartIntravenous route1944-04-10 to 1944-04-17completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1944-06-26Body height188cmS
1944-06-26Body weight83kgS
1944-06-26Body mass index (BMI) [Ratio]23.5kg/m2S
1944-06-26Systolic blood pressure128mm[Hg]S
1944-06-26Diastolic blood pressure78mm[Hg]S
1944-06-26Heart rate70/minS
1944-06-26Respiratory rate16/minS
1944-06-26Body temperature36.7CelS
1944-06-26Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1944-06-26Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma980pg/mL<=125 pg/mLHighS
1944-06-26Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1944-06-26Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
1944-06-26Creatinine [Mass/volume] in Serum or Plasma1.24mg/dL0.74-1.35 mg/dLNormalS
1944-06-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1939)/1.73 sq M66mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1944-06-26Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
1944-06-26Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-16.6 g/dLNormalS
1944-06-26Ferritin [Mass/volume] in Serum or Plasma236ng/mL30-400 ng/mLNormalS
1944-06-26Iron saturation [Mass Fraction] in Serum or Plasma27%20-50%NormalS
1944-06-26Overall summary score [KCCQ-12]64{score}S
1944-06-26Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 1944-06-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell and energetic; weight 83 kg on the wheelchair scale
NeckJugular venous pressure 6 cm
LungsClear
HeartRegular rhythm, rate 70; no S3
ChestNo breast enlargement or tenderness
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1862 findingsactiveconfirmed I11.0S — Synthetic active diagnosis for the teaching episode; the 1944 findings remain D.
Heart failure with reduced ejection fraction, NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic diagnosis confirmed by echocardiogram in the modern episode.
Nicotine dependence, cigarettesactiveconfirmed F17.210S — Synthetic modern diagnosis linked to documented cigarette smoking.
Iron deficiency anemia in heart failure, repleted with intravenous ironresolvedconfirmed D50.9S — Synthetic finding that echoes the documented 1941 anemia; the modern values are S.
Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputedactiveprovisional B91S — Synthetic modern coding of the documented diagnosis; the alternative cause remains R.
Prediabetesactiveconfirmed R73.03S — Synthetic finding from the baseline HbA1c.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBasic metabolic panel1 to 2 weeks after starting or changing sacubitril/valsartan, spironolactone, empagliflozin, or a diuretic; every 3 to 6 months when stableCompleted todayPotassium 4.6, creatinine 1.24 mg/dL, eGFR 66. This is the first panel since sacubitril/valsartan was increased and spironolactone started eleven weeks ago
LaboratoryBasic metabolic panel 1 to 2 weeks after the April changesOnce, after titrating sacubitril/valsartan and starting spironolactoneDeferredNot drawn in the window: the panel planned for the second iron infusion was not done, a deviation from the protocol. Today's potassium and kidney function are normal, so no harm resulted. Corrective action: each medication change now comes with a dated laboratory appointment booked before he leaves
LaboratoryBasic metabolic panel after stopping furosemide1 to 2 weeks after a diuretic changeDueFurosemide stops today while he continues spironolactone and sacubitril/valsartan, which can raise potassium
LaboratoryNT-proBNPSelectively in outpatient follow-upCompleted today980 pg/mL, down from 2850; informs decongestion and prognosis, not used to titrate therapy
LaboratoryHemoglobin, ferritin, and transferrin saturation6 to 8 weeks after intravenous iron; then yearlyCompleted todayHemoglobin 13.6, ferritin 236, transferrin saturation 27 percent: repleted. Drawn ten weeks after the second dose, two weeks after the window, as planned in April; repletion is confirmed, so the delay caused no harm
LaboratoryLipid panel4 to 12 weeks after starting a statinDeferredNot drawn in the window, which closed last week, and not on today's order, a deviation from the lipid protocol. He takes every dose and has no muscle symptoms, and a three-month delay in confirming the response carries little risk. Corrective action: added to the six-month laboratory order
ExaminationBlood pressure, heart rate, weight, jugular venous pressure, edema, lungsEvery visit; every 1 to 2 weeks during titrationCompleted todayEuvolemic at 83 kg
SurveyNYHA functional classEvery visitCompleted todayClass II
SurveyKCCQ-12Every 3 to 6 monthsCompleted today64, up 26 points from baseline
SurveyDepression screen (PHQ-2)PeriodicallyCompleted todayScore 0
ImagingTransthoracic echocardiogram3 to 6 months after therapy is optimizedDuePlanned for the six-month review, three months after today's carvedilol step
Imaging12-lead ECGAt initial evaluation; repeat with device considerationDueStill not on file (deviation recorded in April); needed before the device decision at the six-month review
ReferralCardiac rehabilitationEjection fraction 35 percent or less, NYHA II to IV, after 6 weeks of optimal therapyReferredEligible: ejection fraction 30 percent, NYHA II, three months of therapy, no hospital stay. Referred to a program that adapts training for wheelchair users with arm ergometry and resistance bands
Medication safetySpironolactone and carvedilol safetyEach visit while titratingCompleted todayPotassium 4.6; no breast tenderness; heart rate 70 with no lightheadedness
Medication safetyTobacco use and cessation treatmentEvery visitCompleted todayAbstinent since April; patch course complete
LaboratoryHbA1c, urine albumin-creatinine ratio, and TSHHbA1c and urine albumin yearly; TSH at diagnosisUp to dateDrawn at diagnosis; the urine albumin test is repeated at the six-month review
Self-managementHome blood pressure and daily weight log; low-sodium dietEvery visitCompleted todayLog reviewed; weight-gain action plan given for the stop of furosemide

Goal progress:

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021); USPSTF A and B Recommendations (2026)

Follow-up: Basic metabolic panel in one to two weeks after stopping furosemide. Six-month heart failure review with an echocardiogram, laboratory tests including a lipid panel, and the KCCQ-12. Next scheduled visit 1944-09-25: six-month heart failure review with repeat echocardiogram. [S]